Notice: This company has been marked as potentially delisted and may not be actively trading. Vital Therapies (VTL) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrends VTL vs. GALT, NKTX, DMAC, HRTX, ACTU, GLSI, VSTM, SCPH, LFVN, and FULCShould you be buying Vital Therapies stock or one of its competitors? The main competitors of Vital Therapies include Galectin Therapeutics (GALT), Nkarta (NKTX), DiaMedica Therapeutics (DMAC), Heron Therapeutics (HRTX), Actuate Therapeutics (ACTU), Greenwich LifeSciences (GLSI), Verastem (VSTM), scPharmaceuticals (SCPH), LifeVantage (LFVN), and Fulcrum Therapeutics (FULC). These companies are all part of the "medical" sector. Vital Therapies vs. Galectin Therapeutics Nkarta DiaMedica Therapeutics Heron Therapeutics Actuate Therapeutics Greenwich LifeSciences Verastem scPharmaceuticals LifeVantage Fulcrum Therapeutics Vital Therapies (NASDAQ:VTL) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations, media sentiment, risk and community ranking. Do analysts rate VTL or GALT? Galectin Therapeutics has a consensus price target of $11.00, suggesting a potential upside of 290.76%. Given Galectin Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Galectin Therapeutics is more favorable than Vital Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vital Therapies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Galectin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger valuation and earnings, VTL or GALT? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVital TherapiesN/AN/A-$41.47MN/AN/AGalectin TherapeuticsN/AN/A-$41.07M-$0.73-3.86 Is VTL or GALT more profitable? Galectin Therapeutics' return on equity of 0.00% beat Vital Therapies' return on equity.Company Net Margins Return on Equity Return on Assets Vital TherapiesN/A -235.33% -182.35% Galectin Therapeutics N/A N/A -163.15% Do institutionals & insiders believe in VTL or GALT? 15.5% of Vital Therapies shares are held by institutional investors. Comparatively, 11.7% of Galectin Therapeutics shares are held by institutional investors. 33.9% of Vital Therapies shares are held by insiders. Comparatively, 52.7% of Galectin Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media favor VTL or GALT? In the previous week, Galectin Therapeutics had 15 more articles in the media than Vital Therapies. MarketBeat recorded 15 mentions for Galectin Therapeutics and 0 mentions for Vital Therapies. Galectin Therapeutics' average media sentiment score of 0.04 beat Vital Therapies' score of 0.00 indicating that Galectin Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Vital Therapies Neutral Galectin Therapeutics Neutral Does the MarketBeat Community favor VTL or GALT? Vital Therapies received 22 more outperform votes than Galectin Therapeutics when rated by MarketBeat users. Likewise, 74.40% of users gave Vital Therapies an outperform vote while only 59.32% of users gave Galectin Therapeutics an outperform vote. CompanyUnderperformOutperformVital TherapiesOutperform Votes36974.40% Underperform Votes12725.60% Galectin TherapeuticsOutperform Votes34759.32% Underperform Votes23840.68% Which has more volatility & risk, VTL or GALT? Vital Therapies has a beta of 3.51, indicating that its stock price is 251% more volatile than the S&P 500. Comparatively, Galectin Therapeutics has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. SummaryGalectin Therapeutics beats Vital Therapies on 9 of the 13 factors compared between the two stocks. Ad Colonial Metals“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as we wait for Trump's agenda to kick in…>> YES! Send Me My FREE Gold Guide! Get Vital Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for VTL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VTL vs. The Competition Export to ExcelMetricVital TherapiesPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$44.49M$6.44B$5.05B$8.82BDividend YieldN/A8.11%5.17%4.07%P/E RatioN/A10.61125.0817.74Price / SalesN/A243.751,182.0574.25Price / CashN/A22.1633.7232.53Price / Book3.625.474.684.68Net Income-$41.47M$153.61M$119.45M$226.08M Vital Therapies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VTLVital TherapiesN/A$1.05-1.9%N/A+0.9%$44.49MN/A0.0010GALTGalectin Therapeutics1.7255 of 5 stars$2.82+2.2%$11.00+290.8%+40.6%$176.67MN/A-3.869Analyst UpgradeAnalyst RevisionNews CoverageNKTXNkarta2.2072 of 5 stars$2.50+0.8%$16.50+560.0%-5.0%$176.43MN/A-1.32140DMACDiaMedica Therapeutics1.9215 of 5 stars$4.02-0.5%$7.00+74.1%+62.2%$171.90MN/A-7.1820HRTXHeron Therapeutics3.9786 of 5 stars$1.12-5.9%$5.67+406.0%+9.2%$170.35M$127.04M-6.22300Short Interest ↓ACTUActuate TherapeuticsN/A$8.67-2.6%N/AN/A$169.34MN/A0.0010GLSIGreenwich LifeSciences1.9267 of 5 stars$12.85+0.6%$38.00+195.7%+19.2%$168.91MN/A-16.063VSTMVerastem2.9246 of 5 stars$3.79-4.3%$14.57+284.5%-37.4%$168.69M$2.60M-1.1950Analyst DowngradeSCPHscPharmaceuticals3.8206 of 5 stars$3.36-4.5%$15.00+346.4%-33.0%$168.13M$13.59M-1.7730Analyst RevisionLFVNLifeVantage2.7377 of 5 stars$12.93-4.6%N/A+140.9%$161.88M$200.16M42.38260FULCFulcrum Therapeutics3.5692 of 5 stars$2.99-0.7%$9.33+212.2%-27.5%$161.28M$2.81M-9.71100Analyst RevisionNews Coverage Related Companies and Tools Related Companies GALT Competitors NKTX Competitors DMAC Competitors HRTX Competitors ACTU Competitors GLSI Competitors VSTM Competitors SCPH Competitors LFVN Competitors FULC Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VTL) was last updated on 11/20/2024 by MarketBeat.com Staff From Our PartnersTesla Execs are Freaking OutIt’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands...Angel Publishing | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredAmerica’s Pro-Crypto AgendaCash In On the Pro-Crypto America 27 experts reveal their top picks for 2025 Crypto 101 Media | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | SponsoredThe smart-money is buying this US$1 lithium stockLithium is getting white-hot once again! And that means well-timed investors who position now in the best n...Resource Stock Digest | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vital Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vital Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
